Juan Jesus Carrero Pharm PhD Professor of Epidemiology Cardio-renal Department of Medical Epidemiology and Biostatistics Karolinska Institutet, Stockholm

Study Finds Reduced Kidney Disease Progression with DOACs vs Vitamin K Antagonists

MedicalResearch.com Interview with:

Juan Jesus Carrero Pharm PhD Professor of Epidemiology Cardio-renal Department of Medical Epidemiology and Biostatistics Karolinska Institutet, Stockholm

Dr. Carrero

Juan Jesus Carrero Pharm PhD
Professor of Epidemiology
Cardio-renal Department of Medical Epidemiology and Biostatistics
Karolinska Institutet, Stockholm

MedicalResearch.com: What is the background for this study? What are the main findings?

 Response: Concerns on the possibility of (direct oral anticoagulants)  DOAC-related nephropathy may limit its use.

In this cohort study of non-valvular AF patients from routine clinical practice, initiation of DOAC vs (vitamin K antagonists) VKA was associated with more favorable kidney outcomes, i.e., a lower risk of the composite of kidney failure and sustained 30% eGFR decline, as well as a lower risk of AKI occurrence.

In agreement with trial evidence, we also showed that DOAC vs VKA treatment was associated with a lower risk of major bleeding, but a similar risk of the composite of stroke, systemic embolism or death.

MedicalResearch.com: What should readers take away from your report?

Response: These findings add to emerging evidence on the safety and effectiveness of DOAC administered for atrial fibrillation. 

MedicalResearch.com: What recommendations do you have for future research as a results of this study?

Response: Clinical trials to expand the efficacy and safety of DOACS to persons with Afib on dialysis, a patient group currently left without treatment options.

Disclosures:  have no disclosures related to the topic of investigation. Outside this topic, my institution has received funding from AstraZeneca, ViforPharma, Astellas and Amgen

Citation:

 Cardiorenal Outcomes Among Patients With Atrial Fibrillation Treated With Oral Anticoagulants
Marco Trevisan, PhD, Paul Hjemdahl, MD, Catherine M. Clase, MB BChir MSc, Ype de Jong, MD, Marie Evans, MD, Rino Bellocco, PhD, Edouard L. Fu, MD, and Juan Jesus Carrero, Pharm PhD
American Journal of Kidney Diseases Oct 5 2022

https://doi.org/10.1053/j.ajkd.2022.07.017

The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.

 

 

Last Updated on October 6, 2022 by Marie Benz MD FAAD